Serotonergic modulation of striatal D2 dopamine receptor binding in humans measured with positron emission tomography

Psychopharmacology

Volumn 126, Issue 4, 1996, Pages 277-280

  Tiihonen, Jari ^a   Kuoppamäki, Mikko ^b,c   Någren, Kjell ^c   Bergman, Jörgen ^d   Eronen, Esa ^c   Syvälahti, Erkka ^b,c   Hietala, Jarmo ^c  

^a UNIVERSITY OF EASTERN FINLAND   (Finland)

^b UNIVERSITY OF TURKU   (Finland)

^c TURKU UNIVERSITY HOSPITAL   (Finland)

^d ÅBO AKADEMI UNIVERSITY   (Finland)

Author keywords

Dopamine; Interaction; Positron emission tomography; Raclopride; Serotonin

Indexed keywords

CITALOPRAM; DOPAMINE 2 RECEPTOR; PLACEBO; RACLOPRIDE; RADIOLIGAND; SEROTONIN UPTAKE INHIBITOR;

ADULT; ARTICLE; CAUDATE NUCLEUS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINERGIC TRANSMISSION; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG RECEPTOR BINDING; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PUTAMEN; RANDOMIZED CONTROLLED TRIAL; SEROTONINERGIC SYSTEM; VOLUNTEER;

EID: 0029816246     PISSN: 00333158     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02247377     Document Type: Article

References (17)

1. Arya DK (1994) Extrapyramidal symptoms with selective serotonin re-uptake inhibitors. Br J Psychiatry 165 : 728-733
2. Awazi N, Guldberg HC (1978) On the interaction of 5-hydroxytryptophan and 5-hydroxytryptamine with dopamine metabolism in the rat striatum. Naunyn-Schmiedeberg's Arch Pharmacol 303 : 63-72
3. Baldessarini RJ, Marsh E (1990) Fluoxetine and side effects. Arch Gen Psychiatry 47 : 191-192
4. Benloucif S, Gallaway MP (1991) Facilitation of dopamine release in vivo by serotonin agonists: studies with microdialysis. Eur J Pharmacol 200 : 1-8
5. Dewey SL, Smith GS, Logan J, Alexoff D, Ding Y-S, King P, Pappas N, Brodie JD, Ashby CR Jr (1995) Serotonergic modulation of striatal dopamine measured with positron emission tomography (PET) and in vivo microdialysis. J Neurosci 15 : 821-829
6. 2 dopamine receptors studied by PET a comparison to the equilibrium analysis. J Cereb Blood Flow Metab 9 : 696-708
7. Halldin C, Farde L, Högberg T, Hall H, Ström P, Ohlberg A, Solin O (1991) A comparative PET-study of five carbon-11 or fluorine-18 labelled salicylamides. Preparation and in vivo dopamine D-2 receptor binding. Nucl Med Biol 18 : 871-881
8. 2 receptor characteristics in neuroleptic-naive schizophrenic patients studied with positron emission tomography. Arch Gen Psychiatry 51 : 116-123
9. 2 receptor characteristics in patients with alcohol dependence in vivo. Psychopharmacology 116 : 285-290
10. Hietala, J, Syvälahti E, Vuorio K, Räkkoläinen V, Bergman J, Haaparanta M, Solin O, Kuoppamäki M, Kirvelä O, Ruotsalainen U, Salokangas RKR (1995) Presynaptic dopamine function in striatum of neuroleptic-naive schizophrenic patients. Lancet 346 : 1130-1131
11. 2 receptor-mediated potentiation of dopamine synthesis and central serolonergic deficits. Eur J Pharmacol 238 : 291-296
12. van Praag HM, Kahn RS, Asnis GM et al. (1987) Denosologization of biological psychiatry or the specificity of 5-HT disturbances in psychiatric disorders. J Affect Disord 13 : 1-8
13. 3H-raclopride: implications for positron emission tomography of the human brain. Synapse 3 : 96-97
14. 1 receptor. Eur J Pharmacol 157 : 173-186
15. 3 receptor antagonist, on A9 and A10 dopamine neurons. Eur J Pharmacol 163 : 115-124
16. Spampinato U, Esposito E, Samanin R (1985) Serotonergic agonists reduce dopamine synthesis in the striatum only when the impulse flow of nigro-starital neurons is intact. J Neurochem 454 : 980-982
17. Waldmeier P, Delini-Stula A (1979) Serotonin-dopamine interactions in the nigrostriatal system. Eur J Pharmacol 55 : 363-373